Annual Reports in Medicinal Chemistry

<p>Personal Essay</p> <ol> <p> <li>Reflections on Medicinal Chemistry at Merck, West Point</li> <p>Paul S. Anderson</p> <p> <li>My Path in Seeking New Medicines</li> <p>Peter R. Bernstein</p> <p> <li>Tales of Drug Discovery </li> <p>M. Ross Johnson</p> <p>I. Central Nervous System Diseases</p> <p>Section Editor: Albert J. Robichaud; Sage Therapeutics, Inc. Cambridge, Massachusetts</p> <p> <li>Recent Developments in Targeting Neuroinflammation in Disease</li> <p>Allen T. Hopper, Brian M. Campbell, Henry Kao, Sean A. Pintchovski and Roland G. W. Staal</p> <p> <li>Secretase Inhibitors and Modulators as a Disease Modifying Approach Against Alzheimer’s Disease</li> <p>Harrie J. M. Gijsen and François P. Bischoff</p> <p> <li>mGluR2 Activators and mGluR5 Blockers Advancing in the Clinic for Major CNS Disorders</li> <p>Sylvain Célanire, Guillaume Duvey, Sonia Poli and Jean-Philippe Rocher</p> <p> <li>NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C and GluN2D Subtypes – Recent Results and Developments </li> <p>Kamalesh B. Ruppa, Dalton King and Richard Olson</p> <p> <li>Recent Advances in the Development of PET and SPECT Tracers for Brain Imaging</li> <p>Lei Zhang and Anabella Villalobos</p> <p>II. Cardiovascular and Metabolic Diseases</p> <p>Section Editor: Andy Stamford, Merck Research Laboratories, Kenilworth, New Jersey</p> <p> <li>Case History: Eliquis^TM (Apixaban), a Potent and Selective Inhibitor of Coagulation Factor Xa for the Prevention and Treatment of Thrombotic Diseases</li> <p>Donald J. P. Pinto, Pancras C. Wong, Robert M. Knabb and Ruth R. R. Wexler </p> <p> <li>AMPK Activation in Health and Disease</li> <p>Iyassu K. Sebhat and Robert W. Myers</p> <p> <li>Type-2 Diabetes and Associated Co-Morbidities as an Inflammatory Syndrome</li> <p>Juan C. Jaen, Jay P. Powers and Tim Sullivan</p> <p> <li>Beyond PPARs & Metformin: New Insulin Sensitizers for the Treatment of Type 2 Diabetes</li> <p>Philip A. Carpino and David Hepworth</p> <p>III. Inflammatory Pulmonary and Gastrointestinal Diseases</p> <p>Section Editor: David S. Weinstein, Bristol-Myers Squibb R&D, Princeton, New Jersey</p> <p> <li>Recent Advances in the Discovery and Development of Sphingosine-1-Phosphate-1 Receptor Agonists</li> <p>Alaric J. Dyckman</p> <p> <li>Bifunctional Compounds for the Treatment of COPD </li> <p>Gary Phillips and Michael Salmon</p> <p> <li>Inflammatory Targets for the Treatment of Atherosclerosis </li> <p>Robert O. Hughes, Alessandra Bartolozzi and Hidenori Takahashi</p> <p>IV. Oncology</p> <p>Section Editor: Shelli R. McAlpine, School of Chemistry, University of New South Wales, Sydney, Australia</p> <p> <li>Nanotechnology Therapeutics in Oncology – Recent Developments and Future Outlook</li> <p>Paul F. Richardson</p> <p> <li>Small-Molecule Antagonists of Bcl-2 Family Proteins</li> <p>Sean P. Brown and Joshua P. Taygerly</p> <p> <li>Notch Pathway Modulators as Anti-Cancer Chemotherapeutics</li> <p>Vibhavari Sail and M. Kyle Hadden</p> <p> <li>Anaplastic Lymphoma Kinase (ALK) Inhibitors for the Treatment of ALK-Positive Cancers </li> <p>Kazutomo Kinoshita, Nobuhiro Oikawa and Takuo Tsukuda</p> <p>V. Infectious Diseases</p> <p>Section Editor: John Primeau, Westford, Massachusetts</p> <p> <li>Recent Advances in the Discovery of Dengue Virus Inhibitors</li> <p>Jeremy Green, Upul Bandarage, Kate Luisi and Rene Rijnbrand</p> <p> <li>Non Fluoro-Quinolone Based Inhibitors of Mycobacterial Type II Topoisomerase as Potential Therapeutic Agents for TB</li> <p>Pravin S. Shirude and Shahul Hameed</p> <p> <li>HCV Inhibition Mediated through the Nonstructural Protein 5A (NS5A) Replication Complex </li> <p>Robert Hamatake, Andrew Maynard and Wieslaw M. Kazmierski</p> <p>VI. Topics in Biology</p> <p>Section Editor: John Lowe, JL3Pharma LLC, Stonington, Connecticut</p> <p> <li>Antibody-Drug Conjugates for Targeted Cancer Therapy</li> <p>Victor S. Goldmacher, Thomas Chittenden, Ravi V. J. Chari, Yelena V. Kovtun and John M. Lambert</p> <p> <li>3D Cell Cultures: Mimicking in Vivo Tissues for Improved Predictability in Drug Discovery</li> <p>Indira Padmalayam and Mark J. Suto</p> <p> <li>Virally Encoded G Protein-Coupled Receptors: Overlooked Therapeutic Opportunities?</li> <p>Nuska Tschammer</p> <p> <li>Recent Advances in Wnt/b-Catenin Pathway Small Molecule Inhibitors</li> <p>Daniel D. Holsworth and Stefan Krauss</p> <p>VII. Topics in Drug Design and Discovery</p> <p>Section Editor: Peter R. Bernstein, PhaRmaB LLC, Rose Valley, Pennsylvania</p> <p> <li>Targeted Covalent Enzyme Inhibitors</li> <p>Mark C. Noe and Adam M. Gilbert</p> <p> <li>Drug Design Strategies for GPCR Allosteric Modulators</li> <p>P. Jeffrey Conn, Scott D. Kuduk and Darío Doller</p> <p> <li>Progress in the Development of Non-ATP Competitive Protein Kinase Inhibitors for Oncology</li> <p>Campbell M^cInnes</p> <p>VIII. Trends</p> <p>Section Editor: Joanne Bronson, Bristol-Myers Squibb, Wallingford, Connecticut</p> <p> <li>New Chemical Entities Entering Phase III Trials in 2011</li> <p>Gregory T. Notte</p> <p> <li>To Market, To Market – 2011Joanne Bronson, Murali Dhar, William Ewing and Nils Lonberg</li></ol>